Clinicopathological characteristics
|
n
|
SATB2-AS1 expression
|
P
|
---|
Low expression (n = 66)
|
High expression (n = 65)
|
---|
Age (year)
| | | |
0.379
|
≥ 51
|
55
|
25
|
30
| |
< 51
|
76
|
41
|
35
| |
Menopause
| | | |
0.862
|
No
|
61
|
30
|
31
| |
Yes
|
70
|
36
|
34
| |
LNM
| | | |
0.002
|
No
|
58
|
20
|
38
| |
Yes
|
73
|
46
|
27
| |
Tumor diameter
| | | |
0.003
|
< 2 cm
|
46
|
15
|
31
| |
≥ 2 cm
|
85
|
51
|
34
| |
TNM stage
| | | |
0.008
|
I–II
|
73
|
29
|
44
| |
III–IV
|
58
|
37
|
21
| |
Histological grade
| | | |
0.138
|
G1
|
27
|
11
|
16
| |
G2
|
68
|
38
|
30
| |
G3
|
36
|
17
|
19
| |
Estrogen receptor
|
+
|
58
|
23
|
35
|
0.029
|
–
|
73
|
43
|
30
| |
Progesterone receptor
|
+
|
61
|
24
|
37
|
0.018
|
–
|
70
|
42
|
28
| |
HER2 status
|
–
|
72
|
47
|
35
|
0.337
|
+
|
59
|
29
|
30
| |
-
BC breast cancer, SATB2-AS1 antisense transcript of SATB2 protein, LNM lymph node metastasis, TNM tumor, node and metastasis